Replies to post #107579 on Savvy Trades and Investments

[researcher59]

OGN Q3 results will be interesting .... the big question is how well are their "established brands" holding up to the competition ?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172766183&txt2find=ogn

[hweb2]

OGN does look cheap. But that balance sheet sure is ugly. Can't be helping the stock price. With interest rates continuing to rise, this isn't something you want to read in the earnings PR last month-

As of June 30, 2023, cash and cash equivalents were $326 million, and debt was $8.7 billion.

[researcher59]

OGN -.71 to 16.54, the relentless selloff continues. It keeps getting cheaper every day so I'm not feeling very motivated to add to my small position. The latest news on "The Fly" was positive - new analyst coverage with an "Overweight" rating -

fly (9/21) -

Barclays analyst Balaji Prasad initiated coverage of Organon with an Overweight rating and $28 price target. The firm says Organon is a global play and leader in women's specialty. The company is seeing "rapid growth" in biosimilars that can together offset the decline in its brands portfolio, the analyst tells investors in a research note.